Drug intelligence / Profile preview

debitai bismuth aluminate

Development stage: Unknown
Lead developer: Harbin Pharmaceutical Group Pharmaceutical Factory No.6
Modality: Small Molecules
Administration: Oral

Overview

Debitai is a pharmaceutical preparation containing bismuth aluminate as the active ingredient. Bismuth aluminate is an inorganic compound used primarily for its gastrointestinal protective properties, particularly in the management of gastric and duodenal ulcers and other acid-related disorders. It acts locally in the gut to coat ulcerated or inflamed mucosa, providing a protective barrier against stomach acid and pepsin, thereby promoting healing. Bismuth compounds may also have mild antimicrobial activity against Helicobacter pylori, a bacterium associated with peptic ulcer disease[8].

Brand names: debitai
Other names: debitai bismuth aluminate

Beyond the preview

Go deeper on debitai bismuth aluminate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on debitai bismuth aluminate.

Explore the full profile